The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer. This is Fesik’s second three-year award from the Lustgarten Foundation in support of his research targeting K-Ras, a protein mutated in […]
News: Drug DiscoveryNext Page »
Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.
Somatic mutations, which can occur in any cell except sperm or egg, are not inheritable. Several recent studies have demonstrated that disease-causing mutations commonly alter protein folding, protein stability and protein-protein interactions. It has been difficult, however, to determine which somatic mutations identified in tumor samples “drive” the cancer development and which are just “along […]
Vanderbilt University investigators have discovered a new molecular mechanism that regulates the dynamics of microtubules, which form the cell’s internal skeleton. The unexpected finding, reported in Developmental Cell, has implications for cancer drug discovery,
Three Vanderbilt-Ingram Cancer Center (VICC) investigators have been awarded breast cancer research grants totaling $830,000 from the Susan G. Komen organization.
Human cells are constructed in large part from proteins whose activity can be altered by the incorporation of oxygen in what are known as redox modifications. Detecting these redox modifications as they occur in proteins is delicate work, “like trying to catch a fairy in a jar,” said Daniel Liebler, Ph.D., Ingram Professor of Cancer […]
Targeting a cytokine pathway may offer a way to inhibit breast cancer cell survival and metastasis, study suggests.
Two proteins that act in opposing directions – one that promotes cancer and one that suppresses cancer — regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found. The findings, reported recently in the Journal of Clinical Investigation, point toward potential drug targets and prognostic markers for prostate cancer. “We […]
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. The new study by co-first-authors Kimberly Brown Dahlman, Ph.D., Junfeng Xia, Ph.D., and Katherine Hutchinson, B.S., Vanderbilt-Ingram Cancer Center […]
An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer centers tested the new compound. The results of the […]